Heart failure with preserved ejection fraction, often called HFpEF (pronounced “hef-pef”), is a type of heart failure where the heart pumps out a normal amount of blood with each beat but still can’t meet the body’s demands. The ejection fraction, a measure of how much blood the heart pushes out per squeeze, remains at 50% or above, which is considered normal. Yet the heart is stiff and struggles to relax and fill properly between beats, leading to the same dangerous fluid buildup and debilitating symptoms as other forms of heart failure.
This condition accounts for roughly half of all heart failure cases. It’s more common in older adults, women, and people with obesity, high blood pressure, or diabetes. Because the pumping percentage looks normal on a standard heart scan, HFpEF was historically overlooked or misdiagnosed, sometimes dismissed as simple aging or deconditioning.
How the Heart Fails Despite Normal Pumping
To understand HFpEF, it helps to think of the heart’s job as two separate tasks: squeezing blood out and relaxing to fill back up. In the more widely known form of heart failure (called HFrEF, or “reduced” ejection fraction), the squeezing part weakens and the ejection fraction drops below 40%. In HFpEF, squeezing stays intact. The problem is the filling.
Between each heartbeat, the heart’s main pumping chamber needs to relax quickly so blood can flow in from the lungs. In HFpEF, the walls of that chamber become thick and stiff. At the cellular level, the proteins responsible for letting heart muscle fibers stretch and spring back lose their flexibility. Connective tissue surrounding each muscle cell also changes, becoming more rigid as sugar molecules in the blood form permanent bonds with collagen fibers, a process that accelerates with age and diabetes.
The result is a chamber that resists filling. Blood trying to enter from the lungs meets higher resistance, so pressure backs up into the lungs. That’s what causes the hallmark symptom of breathlessness, especially during physical activity when the heart needs to fill and empty faster. Over time, the elevated pressure can also push fluid into the legs, abdomen, and other tissues.
What HFpEF Feels Like Day to Day
The most common symptom is exercise intolerance, a noticeable drop in what you can physically handle. Activities that were once routine, like climbing a flight of stairs, walking uphill, or carrying groceries, leave you winded and exhausted far sooner than expected. This happens because pressure inside the heart rises sharply during exertion, forcing fluid toward the lungs and limiting how much oxygen reaches working muscles.
Other typical symptoms include:
- Shortness of breath when lying flat or during mild effort
- Swelling in the ankles, feet, or abdomen from fluid retention
- Fatigue that feels disproportionate to the activity
- Rapid or irregular heartbeat, sometimes from atrial fibrillation, which frequently coexists with HFpEF
Because these symptoms overlap with so many other conditions, from being out of shape to lung disease to simple aging, HFpEF often goes unrecognized for months or years. Many people adjust their activity level gradually without realizing how much ground they’ve lost.
Who Is Most at Risk
HFpEF clusters around a specific set of risk factors, nearly all tied to metabolic health. Obesity is one of the strongest drivers. High blood pressure, which forces the heart to push against greater resistance and thickens the chamber walls over time, is present in the vast majority of cases. Diabetes is also extremely common; in one large population study, 57% of HFpEF patients had diabetes. Atrial fibrillation, where the upper chambers of the heart quiver rather than beat in rhythm, both contributes to HFpEF and worsens its symptoms.
Age plays a major role. The stiffening process in heart muscle and connective tissue accelerates with every decade, which is why HFpEF predominantly affects people over 60. Women develop HFpEF more often than men, partly because the female heart tends to respond to high blood pressure by thickening rather than enlarging, and partly because women live longer into the age range where risk is highest.
How HFpEF Is Diagnosed
Diagnosing HFpEF is harder than diagnosing the reduced-ejection-fraction type. With HFrEF, a standard echocardiogram (heart ultrasound) shows a weak pump, and the picture is clear. With HFpEF, the pump looks fine. Doctors have to look deeper for signs that the heart isn’t filling properly.
The echocardiogram remains the starting point, but clinicians focus on specific markers of stiffness rather than pumping strength. One key measurement is the E/e’ ratio, which compares how fast blood flows into the heart with how fast the heart wall moves during filling. A high ratio signals that pressure inside the chamber is elevated even though it’s squeezing normally. Another clue is a very short relaxation time between the closing of one valve and the opening of the next, which suggests the heart is under high pressure.
Because no single test is definitive, a scoring system called the H2FPEF score helps clinicians weigh the evidence. It assigns points based on six factors: a BMI over 30 (2 points), use of two or more blood pressure medications (1 point), presence of atrial fibrillation (3 points), elevated lung artery pressure (1 point), age over 60 (1 point), and an elevated E/e’ ratio on echocardiogram (1 point). The score ranges from 0 to 9. A score of 6 or higher corresponds to a 90% or greater probability of HFpEF.
In ambiguous cases, an exercise stress test with hemodynamic monitoring can unmask the problem. Filling pressures that look borderline at rest often spike dramatically during activity, confirming the diagnosis.
Treatment and What to Expect
For years, HFpEF was considered a condition with no proven drug treatment. Medications that dramatically improved survival in reduced-ejection-fraction heart failure were tested in HFpEF and consistently came up short. That changed with the arrival of a class of drugs originally developed for diabetes: SGLT2 inhibitors, which work by helping the kidneys excrete excess sugar and fluid.
In large clinical trials, SGLT2 inhibitors reduced hospitalizations for heart failure by 26% and all-cause death by 14%, with benefits that held regardless of whether patients had diabetes. These drugs are now a cornerstone of HFpEF treatment. The improvement isn’t just statistical. Patients report better exercise tolerance and fewer episodes of fluid overload.
Beyond medication, managing the conditions that drive HFpEF is critical. Controlling blood pressure reduces the workload on a stiff heart. Losing weight, even a modest amount, can meaningfully lower filling pressures and improve symptoms. Supervised exercise training, while counterintuitive for people who feel winded easily, has consistently shown benefits for functional capacity. Salt and fluid restriction helps prevent the fluid buildup that leads to hospitalizations.
Diuretics remain important for symptom control. They don’t change the underlying disease but relieve congestion by helping the body shed excess fluid, easing breathlessness and swelling during flare-ups.
Long-Term Outlook
HFpEF carries a serious prognosis. A study of Medicare patients hospitalized with heart failure found that five-year mortality was approximately 76% for HFpEF, virtually identical to the rate for reduced-ejection-fraction heart failure. The idea that HFpEF is a “milder” form of heart failure is a misconception rooted in the seemingly normal pumping percentage.
What differs is how patients decline. HFpEF tends to cause death from a broader range of causes, including kidney failure, infections, and cancer, reflecting the fact that it’s closely intertwined with aging and metabolic disease rather than being a purely cardiac problem. Hospitalizations for fluid overload are common and tend to recur, each episode carrying its own risks.
The trajectory varies widely. Some people live for many years with manageable symptoms, especially when weight, blood pressure, and fluid status are well controlled. Others experience a more rapid decline, particularly when multiple comorbidities compound the problem. Early recognition and aggressive management of the underlying metabolic drivers offer the best chance of slowing progression and preserving quality of life.